SEARCH

SEARCH BY CITATION

References

  • 1
    Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B et al. International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010;6:24.
  • 2
    Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012;67:147157.
  • 3
    Zanichelli A, Vacchini R, Badini M, Penna V, Cicardi M. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011;66:192196.
  • 4
    Sheffer AL, Fearon DT, Austen KF. Hereditary angioedema: a decade of management with stanozolol. J Allergy Clin Immunol 1987;80:855860.
  • 5
    Cicardi M, Bergamaschini L, Cugno M, Hack E, Agostoni G, Agostoni A. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol 1991;87:768773.
  • 6
    Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008;100:153161.
  • 7
    Bork K, Hardt J. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol 2011;154:8188.
  • 8
    Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513522 e14.
  • 9
    van Doorn MB, Burggraaf J, van Dam T, Eerenberg A, Levi M, Hack CE et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005;116:876883.
  • 10
    Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S et al. Recombinant human C1 inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010;126:821827.
  • 11
    Moldovan D, Reshef A, Fabiani J, Kivity S, Toubi E, Shlesinger M et al. Efficacy and safety of recombinant human C1 inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Clin Exp Allergy 2012;000:929935.
  • 12
    Zilberberg MD, Nathanson BH, Jacobsen T, Tillotson G. Descriptive epidemiology of hereditary angioedema hospitalizations in the United States, 2004–2007. Allergy Asthma Proc 2011;32:248254.
  • 13
    Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010;31:407414.
  • 14
    Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004;114(3 Suppl):S51S131.
  • 15
    Longhurst HJ, Farkas H, Craig T, Aygoren-Pursun E, Bethune C, Bjorkander J et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010;6:22.
  • 16
    Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1 inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2006;117:904908.
  • 17
    Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996;334:16301634.
  • 18
    Bork K, Witzke G. Long-term prophylaxis with C1 inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1 inhibitor deficiency. J Allergy Clin Immunol 1989;83:677682.
  • 19
    Spath PJ, Wuthrich B, Butler R. Quantification of C1 inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema–evidence of a functionally critical level of C1 inhibitor concentration. Complement 1984;1:147159.
  • 20
    Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976;295:14441448.
  • 21
    Cocchio C, Marzella N. Cinryze a human plasma-derived C1 esterase inhibitor for prophylaxis of hereditary angioedema. P T 2009;34:293328.
  • 22
    Maplethorpe C. CINRYZE (C1 Inhibitor) for routine prophylaxis against HAE attacks. [FDA Briefing document] 2008; Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm094092.pdf.
  • 23
    Hack CE, Relan A, van Amersfoort ES, Cicardi M. Target levels of functional C1 inhibitor in hereditary angioedema. Allergy 2012;67:123130.
  • 24
    Choi G, Soeters MR, Farkas H, Varga L, Obtulowicz K, Bilo B et al. Recombinant human C1 inhibitor in the treatment of acute angioedema attacks. Transfusion 2007;47:10281032.
  • 25
    Hack CE, Mannesse M, Baboeram A, Oortwijn B, Relan A. Immunogenicity assessment of recombinant human C1 inhibitor: an integrated analysis of clinical studies. BioDrugs 2012;26:303313.
  • 26
    Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1 inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009;19:147151.
  • 27
    Aygören-Pürsün E, Martinez-Saguer I, Rusicke E, Klingebiel T, Kreuz W. On demand treatment and home therapy of hereditary angioedema in Germany – the Frankfurt experience. Allergy Asthma Clin Immunol 2010;6:21.
  • 28
    Kreuz W, Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Heller C, Kingebiel T. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 2012;52:100107.
  • 29
    Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol 2007;147:1117.